Drug safety: Further actions needed to improve fda’s postmarket decision-making process

May 9, 2007
GAO_drug_safety_507
172.8 KB

GAO report found that FDA lacked clear and effective processes for making decisions about, and providing management oversight of, postmarket drug safety issues.

IssuesHealth
You Might Also Be Interested In
November 20, 2019
Letter in support of Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
November 12, 2019
Consumer Reports Signs Coalition Letter Urging Surprise Medical Bills Protections Before 2020
October 25, 2019
Consumer organizations letter to DOT and FAA on passenger emergency evacuation test
September 20, 2019
Protect Consumers from Surprise Medical Bills, Prevent Unsustainable Cost Growth